Trial Profile
AVeRT: Anti-PD-1 Monoclonal Antibody (Nivolumab) in Combination With DC Vaccines for the Treatment of Recurrent Grade III and Grade IV Brain Tumors
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 30 Mar 2020
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Dendritic cell vaccines
- Indications Anaplastic astrocytoma; Glioblastoma; Glioma; Oligodendroglioma
- Focus Adverse reactions
- Acronyms AVERT
- 31 May 2019 Results evaluating safety of nivolumab in combination with CMVpp65 mRNA pulsed DC vaccination, published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019).
- 31 May 2019 Status changed from active, no longer recruiting to discontinued as per results published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019).
- 07 Nov 2018 Planned End Date changed from 1 Sep 2018 to 1 Dec 2019.